Toni K Choueiri MD

Genitourinary Oncology, Hematologic Oncology

Director, Lank Center for Genitourinary Oncology; Director, Kidney Cancer Center, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, Harvard Medical School (@DrChoueiri)

Join to view full profile

450 Brookline av, Dana 929Boston, MA 02115
Phone+1 617-632-5456
Fax+1 617-632-2167

Dr. Choueiri is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Choueiri's full profile Already have an account?

Summary

Dr. Toni Choueiri is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dana-Farber Cancer Institute. He received his medical degree from St Joseph's University Medical School and has been in practice 17 years. He also speaks multiple languages, including Arabic and French. He specializes in genitourinary oncology (kidney, prostate, bladder and testicular cancers). He is a Professor of Medicine at Harvard Medical School.

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007
Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
St Joseph's University Medical SchoolClass of 2000

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2006 - 2027
NH State Medical License 2024 - 2026
RI State Medical License 2020 - 2020
OH State Medical License 2001 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
COMPLETED
PHASE2
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
COMPLETED
PHASE2
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
COMPLETED
PHASE3

Publications & Presentations

PubMed

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Rana R McKay, Karla V Ballman, Pamela J Atherton, Archana Ajmera, Tareq Al Baghdadi
Journal of Clinical Oncology. 2026-08-20
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, Sayed Matar, Opeyemi A Jegede
Clinical Cancer Research. 2026-08-14
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.
David D Yang, Aya Abdelnaser, Alexander J Haas, Jeremiah Wala, Alfred A Barney
Clinical Cancer Research. 2026-08-14

Journal Articles

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic
Toni Choueiri, MD, JAMA Oncology
Rethinking Clinical Trials Reform During the COVID-19 Pandemic
Chadi Nabhan, Toni K Choueiri, JAMA Oncology

Lectures

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell ca...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Efficacy of Savolitinib vs Sunitinib in Patients with MET-Driven Papillary Renal Cell Carcinoma
Toni Choueiri, MD, JAMA Oncology
https://www.doximity.com/articles/ba81e72a-1a08-424c-9605-ecfc7add2d39
UpToDate, Wolters Kluwer Health - 2013-02-21

Authored Content

Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

What Would “The Pitt: Oncology” Really Look Like?August 24th, 2026
Merck's Welireg-Keytruda Pairing Sticks the Landing in Adjuvant Kidney Cancer Treatment with New FDA NodJune 15th, 2026
Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American PhysiciansApril 20th, 2026

Grant Support

Optimizing neoadjuvant/adjuvant anti-PD-1 therapy for localized Renal Cell CarcinomaBRIGHAM AND WOMEN'S HOSPITAL2026–2031
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitorsDANA-FARBER CANCER INST2024–2029
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinomaDANA-FARBER CANCER INST2022–2027